ArticleOncology letters2026
Effect and safety analysis of raltitrexed peritoneal perfusion in patients with intermediate and advanced colorectal cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CC) is a major global health burden, and effective management of intermediate and advanced stages remains a clinical challenge. The present study investigated the effect and safety of peritoneal raltitrexed infusion in patients with intermediate and advanced CC. Data from 80 patients with intermediate and advanced CC who visited the Affiliated Hospital of Jiujiang University (Jiujiang, China) between August 2018 and April 2021 were retrospectively analysed. Among them, 42 patients were administered raltitrexed peritoneal infusion as the observation group (OG), and the remaining 38 patients were administered equal amounts of saline as the control group (CG) to compare therapeutic effects. Changes in routine blood indicators [such as number of white blood cells (WBCs), neutrophils (NEs), red blood cells (RBCs) and platelets (PLTs)] and tumour markers (carcinoembryonic antigen and cancer antigen 19-9) before and after 3 days of treatment were compared. Adverse reactions that occurred during treatment were also recorded. Compared with those before surgery, WBC and NE counts were significantly lower (P<0.05), and RBC and PLT counts were significantly greater (P<0.05) in both groups after surgery. The counts in the CG were markedly greater than those in the OG after surgery (P<0.05). Tumour marker levels were significantly higher before surgery than after surgery in both groups (P<0.05). The patients in the CG had a significantly lower disease remission rate than those in the OG (P=0.014). In conclusion, raltitrexed peritoneal infusion chemotherapy is effective and safe for the treatment of patients with intermediate and advanced CC; it can effectively reduce serum tumour marker levels and adverse reaction incidence and improve the survival quality of patients. Raltitrexed peritoneal infusion chemotherapy thus exhibits high clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.